NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis $2.72 +0.13 (+5.02%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Erasca Stock (NASDAQ:ERAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Erasca alerts:Sign Up Key Stats Today's Range$2.62▼$2.7250-Day Range$2.44▼$3.1052-Week Range$1.51▼$3.45Volume1.15 million shsAverage Volume1.62 million shsMarket Capitalization$768.40 millionP/E RatioN/ADividend YieldN/APrice Target$6.10Consensus RatingModerate Buy Company OverviewErasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Erasca Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreERAS MarketRank™: Erasca scored higher than 52% of companies evaluated by MarketBeat, and ranked 558th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingErasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageErasca has only been the subject of 2 research reports in the past 90 days.Read more about Erasca's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Erasca are expected to grow in the coming year, from ($0.91) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Erasca's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.21% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 0.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.21% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 0.03%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.30 News SentimentErasca has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Erasca this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Erasca's insider trading history. Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Stock News HeadlinesErasca Insiders Added US$1.95m Of Stock To Their HoldingsOctober 31 at 2:07 PM | finance.yahoo.comThe Goldman Sachs Group Raises Erasca (NASDAQ:ERAS) Price Target to $3.50October 29, 2024 | americanbankingnews.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Erasca announces clinical progress for naporafenibOctober 25, 2024 | markets.businessinsider.comErasca Announces Strong Momentum for Naporafenib and RAS Targeting FranchiseOctober 24, 2024 | markets.businessinsider.comErasca: New Focus After Restructuring, But Need More DifferentiationSeptember 30, 2024 | seekingalpha.comErasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the companySeptember 24, 2024 | finance.yahoo.comErasca to Present at Upcoming Investor Conferences in SeptemberAugust 29, 2024 | finance.yahoo.comSee More Headlines ERAS Stock Analysis - Frequently Asked Questions How have ERAS shares performed this year? Erasca's stock was trading at $2.13 on January 1st, 2024. Since then, ERAS stock has increased by 27.7% and is now trading at $2.72. View the best growth stocks for 2024 here. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.12. When did Erasca IPO? Erasca (ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. Who are Erasca's major shareholders? Top institutional investors of Erasca include SG Americas Securities LLC (0.04%), Exchange Traded Concepts LLC (0.03%), China Universal Asset Management Co. Ltd. (0.03%) and Palumbo Wealth Management LLC (0.01%). Insiders that own company stock include Jonathan E Lim, Bihua Chen, Alexander W Casdin and Valerie Denise Harding Start. View institutional ownership trends. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Erasca own? Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/12/2024Today11/02/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees126Year FoundedN/APrice Target and Rating Average Stock Price Target$6.10 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+124.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.38% Return on Assets-37.01% Debt Debt-to-Equity RatioN/A Current Ratio16.79 Quick Ratio16.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book1.30Miscellaneous Outstanding Shares282,500,000Free Float221,766,000Market Cap$768.40 million OptionableOptionable Beta1.16 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ERAS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.